Costa, NunoPires, Ana E.Gabriel, Ana M.Goulart, Luiz F.Pereira, ClaraLeal, BárbaraQueiros, Ana C.Chaara, WahibaMoraes-Fontes, Maria F.Vasconcelos, CarlosFerreira, CarlosMartins, JorgeBastos, MarinaSantos, Maria J.Pereira, Maria A.Martins, BertaLima, MargaridaJoão, CristinaSix, AdrienDemengeot, JocelyneFesel, Constantin2016-07-052016-07-052012-10-14Costa, N et al. J Clin Immunol (2013) 33: 349. doi:10.1007/s10875-012-9816-7http://hdl.handle.net/10400.7/676Intravenous IgG (ivIg) is a therapeutic alternative for lupus erythematosus, the mechanism of which remains to be fully understood. Here we investigated whether ivIg affects two established sub-phenotypes of SLE, namely relative oligoclonality of circulating T-cells and reduced activity of CD4 + Foxp3+ regulatory T-cells (Tregs) reflected by lower CD25 surface density.engAdultForkhead Transcription FactorsHumansInterleukin-2 Receptor alpha SubunitLongitudinal StudiesLupus Erythematosus, SystemicMiddle AgedReceptors, Antigen, T-Cell, alpha-betaT-Lymphocyte SubsetsT-Lymphocytes, RegulatoryYoung AdultImmunoglobulins, IntravenousBroadened T-cell Repertoire Diversity in ivIg-treated SLE Patients is Also Related to the Individual Status of Regulatory T-cellsjournal article10.1007/s10875-012-9816-7